IP Library Granted Patent US 11,033,407
Granted Patent B2
US 11,033,407 · App. 16/885,689 · Granted Jun 15, 2021

Methods, devices, and systems for the fabrication of materials and tissues utilizing electromagnetic radiation

Inventors: Ricardo D. Solorzano (Garnet, PA); Sohaib K. Hashmi (Philadelphia, PA); Daniel Cabrera (San Francisco, CA)
Assignee: ALLEVI, INC.
A61F2/5044A61L27/26A61L27/3834B29C64/112B29C64/20B29C64/255B29C64/264B29C64/295B33Y70/00B33Y80/00B41J2/04C12M21/08C12M33/00C12M33/04C12N5/0062C12N5/0662A61F2002/505A61L2430/14B29K2071/02B29K2995/0056B29L2031/7532B41J2002/041C12N2513/00C12N2533/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,033,407
App. No.
16/885,689
Granted
Jun 15, 2021
Kind
B2
Abstract

The present invention provides a three-dimensional bioprinter for fabricating cellular constructs such as tissues and organs using electromagnetic radiation (EMR) at or above 405 nm. The bioprinter includes a material deposition device comprising a cartridge for receiving and holding a composition which contains biomaterial that cures after exposure to EMR. The bioprinter also includes an EMR module that emits EMR at a wavelength of about 405 nm or higher. Also provided is a bioprinter cartridge which contains cells and a material curable at a wavelength of about 405 nm or greater. The cells are present in a chamber and are extruded through an orifice to form the cellular construct.

Claims (29)

1. A method for printing a three-dimensional structure comprising:

providing a composition comprising biomaterial that cures after exposure to electromagnetic radiation (EMR) at or above 405 nm in a cartridge-extruder assembly of a bioprinter;

extruding the composition from the cartridge-extruder assembly onto a receiving plate positioned below the cartridge-extruder assembly; and

curing the extruded composition by applying EMR at a wavelength of about 405 nm or higher to the extruded composition.

2. The method of claim 1 , further comprising simultaneously extruding the composition and curing the extruded composition.

3. The method of claim 1 , wherein curing the extruded composition by applying EMR to the extruded composition for between about 1 to 120 seconds.

4. The method of claim 1 , further comprising:

maintaining the temperature of at least one of the cartridge-extruder assembly and the receiving plate between about −10 to 300° C.

5. The method of claim 1 , wherein extruding the composition from the cartridge-extruder assembly onto the receiving plate further comprises generating a pressure using at least one of a piston, compressed gas, hydraulics, air compressor, piezo-electronics, and inkjet dispensing extrusions.

6. The method of claim 1 , further comprising, extruding a second composition from a second cartridge-extruder assembly onto the receiving plate.

7. The method of claim 6 , wherein the second composition from the second cartridge-extruder assembly comprises a second biomaterial that cures after exposure to electromagnetic radiation (EMR) at or above 405 nm or the second composition from the second cartridge-extruder assembly comprises the second biomaterial at a different concentration than a concentration of the biomaterial in the cartridge-extruder assembly.

8. The method of claim 6 , wherein the second composition from the second cartridge-extruder assembly comprises the second biomaterial that cures after exposure to EMR at or above 405 nm at the same concentration as a concentration of the biomaterial in the cartridge-extruder assembly.

9. The method of claim 1 , wherein said composition further comprises at least one of an extrusion agent which is curable at a wavelength of about 405 nm or greater, a photo-initiator which is curable at a wavelength of about 405 nm or greater, a viscosity agent, or a biocompatible agent.

10. The method of claim 9 , wherein said extrusion agent is at least one of polyoxyalkylene, diacrylate, methacrylate, norbornene, gelatin, methacrylate, methacrylated hyaluronic acid, hydroxyethyl-methacrylate-derivatized-dextran, p(HPMAm-lactate)-PEG, gold nanorods, carbon nanotubes, collagen, polyethylene oxide, poly-caprolactone, and poly(L)-lactic acid.

11. The method of claim 9 , wherein said photo-initiator is lithium phenyl-2,4,6-trimethylbenzoylphosphinate or one or more of the following: 2-Hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone, 4-(2-hydroxyethoxy)benzoyl, Isopropanol-2-yl, phenyl-2,4,6-trimethylbenzoylphosphinate, 2,4,6-trimethylbenzoyl, and phenylphosphinoyl.

12. The method of claim 9 , wherein said viscosity agent is at least one of poly(ethylene oxide), gelatin, Pluronic F-127, and hyaluronic acid.

13. The method of claim 9 , wherein the biocompatible agent comprises cells.

14. The method of claim 1 , wherein the extruded composition comprises a tissue structure configured for at least one of drug discovery and implantation.

15. A method for constructing a three-dimensional structure comprising:

providing, in a first cartridge-extruder assembly of a bioprinter, a first composition comprising structural materials that cure after exposure to electromagnetic radiation (EMR) at or above 405 nm;

providing, in a second cartridge-extruder assembly of the bioprinter, a second composition comprising biomaterials that cure after exposure to EMR at or above 405 nm;

extruding the first composition onto a receiving plate positioned below at least one of the first and second cartridge-extruder assemblies;

extruding the second composition onto the extruded first composition to form a multi-layered three-dimensional structure; and

curing the multi-layered three-dimensional structure by applying EMR at a wavelength of about 405 nm or higher.

16. The method of claim 15 , wherein said second composition further comprises at least one of an extrusion agent which is curable at a wavelength of about 405 nm or greater, a photo-initiator which is curable at a wavelength of about 405 nm or greater, viscosity agent, or a biocompatible agent.

17. The method of claim 16 , wherein said extrusion agent is at least one of polyoxyalkylene, diacrylate, methacrylate, norbornene, gelatin, methacrylate, methacrylated hyaluronic acid, hydroxyethyl-methacrylate-derivatized-dextran, p(HPMAm-lactate)-PEG, gold nanorods, carbon nanotubes, collagen, polyethylene oxide, poly-caprolactone, and poly(L)-lactic acid.

18. The method of claim 16 , wherein said photo-initiator is lithium phenyl-2,4,6-trimethylbenzoylphosphinate or one or more of the following: 2-Hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone, 4-(2-hydroxyethoxy)benzoyl, Isopropanol-2-yl, phenyl-2,4,6-trimethylbenzoylphosphinate, 2,4,6-trimethylbenzoyl, and phenylphosphinoyl.

19. The method of claim 16 , wherein said viscosity agent is at least one of poly(ethylene oxide), gelatin, Pluronic F-127, and hyaluronic acid.

20. The method of claim 16 , wherein the biocompatible agent comprises cells.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jun 3, 2021
From: BROADOAK FUND IV, LLC
To: ALLEVI, INC
Reel/Frame 056433/0635 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2021
From: ALLEVI, INC
To: 3D SYSTEMS, INC.
Reel/Frame 056433/0814 →
SECURITY INTEREST Recorded Mar 15, 2021
From: ALLEVI INC.
To: BROADOAK FUND IV, LLC
Reel/Frame 055591/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2021
From: SOLORZANO, RICARDO D.; HASHMI, SOHAIB K.; CABRERA, DANIEL
To: BIOBOTS, INC.
Reel/Frame 055350/0444 →
CHANGE OF NAME Recorded Feb 22, 2021
From: BIOBOTS, INC.
To: ALLEVI, INC,
Reel/Frame 055350/0671 →
Continuity (5)
Continuation 16725127 · Dec 23, 2019
Continuation 15128632
Provisional Application 61969832 · Mar 25, 2014
Provisional Application 62046279 · Sep 5, 2014
Related Publication 20200352743A1 · Nov 12, 2020